Seromycin Related Published Studies
Well-designed clinical trials related to Seromycin (Cycloserine)
A novel treatment for tinnitus and tinnitus-related cognitive difficulties using
computer-based cognitive training and D-cycloserine. [2015]
Cognitive-behavioural therapy with post-session D-cycloserine augmentation for
paediatric obsessive-compulsive disorder: pilot randomised controlled trial. [2014]
D-cycloserine enhancement of exposure therapy for social anxiety disorder depends
on the success of exposure sessions. [2013]
D-cycloserine enhancement of fear extinction is specific to successful exposure
sessions: evidence from the treatment of height phobia. [2013]
Effects of D-cycloserine on cue-induced craving and cigarette smoking among
concurrent cocaine- and nicotine-dependent volunteers. [2013]
A randomized, placebo-controlled laboratory study of the effects of D-cycloserine
on craving in cocaine-dependent individuals. [2013]
Exposure therapy, D-cycloserine, and functional magnetic resonance imaging in
patients with snake phobia: a randomized pilot study. [2012]
A controlled trial of the adjunct use of D-cycloserine to facilitate cognitive
behavioral therapy outcomes in a cocaine-dependent population. [2012]
Effect of D: -cycloserine and valproic acid on the extinction of reinstated fear-conditioned responses and habituation of fear conditioning in healthy humans: a randomized controlled trial. [2011.12]
A pilot study of the effectiveness of D-cycloserine during cue-exposure therapy in abstinent alcohol-dependent subjects. [2011.07]
D-cycloserine facilitates procedural learning but not declarative learning in healthy humans: a randomized controlled trial of the effect of D-cycloserine and valproic acid on overnight properties in the performance of non-emotional memory tasks. [2011.05]
Characterization of the interactive effects of glycine and D-cycloserine in men: further evidence for enhanced NMDA receptor function associated with human alcohol dependence. [2011.02]
Effect of D-cycloserine and valproic acid on the extinction of reinstated
fear-conditioned responses and habituation of fear conditioning in healthy
humans: a randomized controlled trial. [2011]
A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. [2010.12.01]
A Preliminary Study of D-Cycloserine Augmentation of Cognitive-Behavioral Therapy in Pediatric Obsessive-Compulsive Disorder. [2010.09.01]
Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. [2010.07]
The N-methyl-D-aspartate receptor co-agonist D-cycloserine facilitates declarative learning and hippocampal activity in humans. [2010.06.15]
D-cycloserine for the augmentation of an attentional training intervention for trait anxiety. [2010.05]
Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. [2010.02.15]
Efficacy of D-Cycloserine for Enhancing Response to Cognitive-Behavior Therapy for Panic Disorder. [2009.10.05]
An fMRI study examining effects of acute D-cycloserine during symptom provocation in spider phobia. [2009.10]
D-cycloserine and cocaine cue reactivity: preliminary findings. [2009]
A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. [2008.03.15]
Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. [2008.03]
D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. [2007.10.15]
A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. [2007.09]
D-Cycloserine and performance under different states of anxiety in healthy volunteers. [2007.09]
D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. [2007.07]
A randomized controlled trial of the effect of D-cycloserine on extinction and fear conditioning in humans. [2007.04]
A randomized controlled trial of the effect of d-cycloserine on extinction and fear conditioning in humans. [2006.09.06]
A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. [2006.07.07]
Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. [2006.03]
A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. [2005.04]
Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. [2005.01.30]
Effects of D-cycloserine on negative symptoms in schizophrenia. [2004.12.01]
Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. [2004.11]
Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. [2002.12]
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. [2002.03]
Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. [2001.08]
Bioequivalence assessment of closerin capsule to dura seromycin capsule of cycloserine after a single oral dose administration to healthy male volunteers. [2000.10]
IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. [2000.03.01]
Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. [1999.03]
A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. [1999.02.15]
A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. [1999.01]
The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers. [1998.07]
A preliminary study of D-cycloserine treatment in Alzheimer's disease. [1998.03]
Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. [1997.05]
D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. [1996.10]
Evaluation of cycloserine in the treatment of Alzheimer's disease. [1995.10]
Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease. [1995.02]
D-cycloserine treatment of Alzheimer disease. [1994.09]
Well-designed clinical trials possibly related to Seromycin (Cycloserine)
Impact of DCS-facilitated cue exposure therapy on brain activation to cocaine
cues in cocaine dependence. [2013]
Evaluation of the glycine transporter inhibitor Org 25935 as augmentation to
cognitive-behavioral therapy for panic disorder: a multicenter, randomized,
double-blind, placebo-controlled trial. [2012]
A role for glutamate in subjective response to smoking and its action on inhibitory control. [2011.07]
Different antibiotic regimens for treating asymptomatic bacteriuria in pregnancy. [2010.09.08]
[The research network PANIC-NET: improving the treatment of panic disorder - from a better understanding of fear circuit mechanisms to more effective psychological treatment and routine care] [2009.03]
Limited impact of homeostatic plasticity on motor learning in humans. [2008]
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. [2006.09.15]
D-alanine added to antipsychotics for the treatment of schizophrenia. [2006.02.01]
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. [2005.11]
Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. [2005.08]
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. [2004.03.01]
Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. [2004]
Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions. [2001.11]
Placebo-controlled trial of glycine added to clozapine in schizophrenia. [2000.05]
D-serine added to clozapine for the treatment of schizophrenia. [1999.11]
Rifabutin (ansamycin LM427) for the treatment of pulmonary Mycobacterium avium complex. [1990.04]
Other research related to Seromycin (Cycloserine)
Extinction learning as a moderator of d-cycloserine efficacy for enhancing
exposure therapy in posttraumatic stress disorder. [2015]
Prescriptive variables for d-cycloserine augmentation of exposure therapy for
posttraumatic stress disorder. [2014]
Combining d-cycloserine with motor training does not result in improved general
motor learning in neurologically intact people or in people with stroke. [2014]
Randomized placebo-controlled D-cycloserine with cognitive behavior therapy for
pediatric posttraumatic stress. [2014]
Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and
preliminary results of a randomized pilot trial of D-cycloserine-augmented
behavior therapy. [2013]
D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for
social anxiety disorder. [2013]
Augmentation of exposure therapy with post-session administration of
D-cycloserine. [2013]
Valproic acid but not D-cycloserine facilitates sleep-dependent offline learning
of extinction and habituation of conditioned fear in humans. [2013]
A randomized placebo-controlled trial of D-cycloserine and exposure therapy for
posttraumatic stress disorder. [2012]
A randomized placebo-controlled trial of D-cycloserine to enhance exposure
therapy for posttraumatic stress disorder. [2012]
Cue exposure and response prevention with heavy smokers: a laboratory-based randomised placebo-controlled trial examining the effects of D-cycloserine on cue reactivity and attentional bias. [2011.11.22]
D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. [2011.09]
Changes in cue reactivity and attentional bias following experimental cue exposure and response prevention: a laboratory study of the effects of D-cycloserine in heavy drinkers. [2011.09]
D-cycloserine facilitates extinction of cocaine self-administration in rats. [2011.09]
Effects of d-Cycloserine on Craving to Alcohol Cues in Problem Drinkers: Preliminary Findings. [2011.08.18]
Development and validation of a selective and sensitive LC-MS/MS method for determination of cycloserine in human plasma: application to bioequivalence study. [2011.08.01]
D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. [2011.08]
D-cycloserine selectively decreases nicotine self-administration in rats with low baseline levels of response. [2011.04]
D-cycloserine facilitation of cognitive behavioral therapy for delusions in
schizophrenia. [2011]
Anxioselective profile of glycineB receptor partial agonist, D-cycloserine, in plus-maze-naive but not plus-maze-experienced mice. [2010.11.10]
The effect of D-cycloserine on immediate vs. delayed extinction of learned fear. [2010.10.22]
D-cycloserine reduces the context specificity of pavlovian extinction of cocaine cues through actions in the nucleus accumbens. [2010.08.04]
Effect of D-cycloserine on spatial learning performance and memory function-related gene expression in mice following toluene exposure. [2010.06.01]
Previous stress attenuates the susceptibility to Midazolam's disruptive effect on fear memory reconsolidation: influence of pre-reactivation D-cycloserine administration. [2010.04]
D-cycloserine improves functional outcome after traumatic brain injury with wide therapeutic window. [2010.03.10]
Propranolol and D-cycloserine as adjunctive medications in reducing dental fear in sedation practice. [2010.01]
D-cycloserine deters reacquisition of cocaine self-administration by augmenting extinction learning. [2010.01]
A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy
in pediatric obsessive-compulsive disorder. [2010]
Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced
with d-cycloserine. [2010]
D-cycloserine for the augmentation of an attentional training intervention for
trait anxiety. [2010]
Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy
for panic disorder. [2010]
D-cycloserine into the BLA reverses the impairing effects of exposure to stress on the extinction of contextual fear, but not conditioned taste aversion. [2009.10.27]
D-Cycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: a pilot investigation. [2009.10.01]
D-cycloserine facilitation of fear extinction and exposure-based therapy might rely on lower-level, automatic mechanisms. [2009.10.01]
|